Background: The CXCL10/CXCR3 signalling mediates paracrine interactions between tumour and stromal cells that govern leukocyte trafficking and angiogenesis. Emerging data implicate noncanonical CXCL10/CXCR3 signalling in tumourigenesis and metastasis. However, little is known regarding the role for autocrine CXCL10/CXCR3 signalling in regulating the metastatic potential of individual tumour clones.
Methods: We performed transcriptomic and cytokine profiling to characterise the functions of CXCL10 and CXCR3 in tumour cells with different metastatic abilities. We modulated the expression of the CXCL10/CXCR3 pathway using shRNA-mediated silencing in both in vitro and in vivo models of B16F1 melanoma. In addition, we examined the expression of CXCL10 and CXCR3 and their associations with clinical outcomes in clinical data sets derived from over 670 patients with melanoma and colon and renal cell carcinomas.
Results: We identified a critical role for autocrine CXCL10/CXCR3 signalling in promoting tumour cell growth, motility and metastasis. Analysis of publicly available clinical data sets demonstrated that coexpression of CXCL10 and CXCR3 predicted an increased metastatic potential and was associated with early metastatic disease progression and poor overall survival.
Conclusion: These findings support the potential for CXCL10/CXCR3 coexpression as a predictor of metastatic recurrence and point towards a role for targeting of this oncogenic axis in the treatment of metastatic disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506383 | PMC |
| http://dx.doi.org/10.1038/bjc.2015.193 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CXCL10 Promotes Spinal Macrophage Recruitment via the JAK/STAT3 Pathway to Induce Pain in Experimental Autoimmune Prostatitis.
Cell Prolif
December 2024
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
The aim is to explore the mechanisms underlying pain development in chronic prostatitis and identify therapeutic targets for pain management in patients with chronic prostatitis. RNA sequence of the spinal cord dorsal horns and proteomic analysis of spinal macrophages of experimental autoimmune prostatitis (EAP) mice were conducted to identify pain-related genes, proteins and signalling pathways. The clodronate liposome, CXCR3 and P-STAT3 inhibitors, NGF antibody and cromolyn sodium were used to investigate the roles of the CXCL10/CXCR3, JAK/STAT3 and NGF/TrKA pathways in spinal macrophage recruitment and pain response.
View Article and Find Full Text PDFRenal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis.
Signal Transduct Target Ther
November 2024
Key Laboratory of Drug Metabolism and Pharmacokinetics, Haihe Laboratory of Cell Ecosystem, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Human umbilical cord mesenchymal stem cells (hUC-MSCs) have shown potential as a therapeutic option for lupus nephritis (LN), particularly in patients refractory to conventional treatments. Despite extensive translational research on MSCs, the precise mechanisms by which MSCs migrate to the kidney and restore renal function remain incompletely understood. Here, we aim to clarify the spatiotemporal characteristics of hUC-MSC migration into LN kidneys and their interactions with host cells in microenvironment.
View Article and Find Full Text PDFManganese improves CD8 T cell recruitment via cGAS-STING in hepatocellular carcinoma.
Int Immunopharmacol
December 2024
Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, Xinjiang, China; NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases, The First Affiliated Hospital/Shihezi University School of Medicine, Shihezi, Xinjiang, China. Electronic address:
Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide. Chemotherapy using cisplatin, a drug that damages deoxyribonucleic acid (DNA), is not very effective in treating HCC due to its side effects and drug resistance. Manganese (Mn), a trace element, has been shown to enhance immune responses, but its ability to improve cisplatin-induced antitumor immunity in HCC remains unclear.
View Article and Find Full Text PDFIs modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?
Neuro Oncol
January 2025
Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Article Synopsis
- The study highlights a shift in immunology focus from adaptive immune cells to the role of myeloid cells in tumors like glioblastoma, which lack T cells and are dominated by immunosuppressive cells.
- It discusses potential therapeutic strategies targeting myeloid-specific immune checkpoints, alongside some shared targets with adaptive immunity.
- By reviewing existing research on the effects of various immune checkpoint pathways, the authors aim to identify and prioritize new treatment options for glioblastoma.
Hepatocyte-specific Smad4 deficiency inhibits hepatocarcinogenesis by promoting CXCL10/CXCR3-dependent CD8- T cell-mediated anti-tumor immunity.
Theranostics
September 2024
The College of Life Science and Bioengineering, Beijing Jiaotong University, Beijing, China.
Article Synopsis
- Smad4 is an important factor in the TGF-β pathway and plays conflicting roles in liver cancer (HCC), but its specific function in liver cells remains unclear.
- A study using a mouse model showed that deleting Smad4 in liver cells resulted in fewer and smaller tumors, less fibrosis, and enhanced immune response with increased CD8 T cell activity.
- Findings suggest that Smad4 promotes liver cancer development by affecting immune cell behavior and metabolic pathways, indicating it could be a target for HCC treatment and prevention.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!